	Application No.	Applicant(s)
	Application No.	Applicant(s)
Nation of Allawahility	10/637,190	HAFFNER ET AL.
Notice of Allowability	Examiner	Art Unit
·	Rebecca L. Anderson	1626
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>RCE filed 31 March 2005</u> .		
2. The allowed claim(s) is/are 16 and 36.		
3. A The drawings filed on <u>08 August 2003</u> are accepted by the Examiner.		
<ul> <li>4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) ☐ All b) ☐ Some* c) ☐ None of the:</li> <li>1. ☐ Certified copies of the priority documents have been received.</li> <li>2. ☐ Certified copies of the priority documents have been received in Application No</li> <li>3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).</li> </ul>		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
6. CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached		
1) ☐ hereto or 2) ☐ to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)		
1. Notice of References Cited (PTO-892)	<ol><li>5. Notice of Informal Pa</li></ol>	atent Application (PTO-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. Interview Summary	(PTO-413),
3. Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date 31 March 2005	Paper No./Mail Date 8), 7. ⊠ Examiner's Amendr	e nent/Comment
4. ☐ Examiner's Comment Regarding Requirement for Deposit	8. 🛛 Examiner's Stateme	nt of Reasons for Allowance
of Biological Material	9.  Other	

Application/Control Number: 10/637,190

Art Unit: 1626

### **DETAILED ACTION**

Claims 16 and 36 are currently pending in the instant application. Claims 16 and 36 are allowable over the prior art of record.

## Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under *Ex Parte Quayle*, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on 31 March 2005 has been entered.

# Inventorship

In view of the papers filed 31 March 2005, it has been found that this nonprovisional application, as filed, through error and without deceptive intent, improperly set forth the inventorship, and accordingly, this application has been corrected in compliance with 37 CFR 1.48(c) The inventorship of this application has been changed by adding the following inventors:

- Steven Gerard Blanchard
- 2. Steven A. Kliewer
- 3. Jurgen M. Lehmann
- 4. Derek M. Parks
- 5. Julie Beth Stimmel

The application will be forwarded to the Office of Initial Patent Examination (OIPE) for issuance of a corrected filing receipt, and correction of Office records to reflect the inventorship as corrected.

### **EXAMINER'S AMENDMENT**

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

The application has been amended as follows:

- 1. Please replace the first paragraph on page one of the specification with the following paragraph to insert the patent number of the prior copending application.
- --This application is a continuation of Application No. 09/868,397 filed June 18, 2001, now Patent No. 6,639,078, which is a United States National Phase Application of International Application No. PCT/US99/30947 filed December 22, 1999, which claims priority from Provisional Application NO. 60/135,097 filed December 23, 1998.--

### Reasons for Allowance

The following is an examiner's statement of reasons for allowance. This invention relates to a method of lowering serum triglycerides in a mammal comprising administering to a mammal in need thereof an effective amount of the formula as found in claim 36. The present specification provides enablement for the lowering of serum triglycerides in a mammal by the disclosure that the compounds recited in the claims

Application/Control Number: 10/637,190

Art Unit: 1626

are FXR agonists and that administration of such compounds can reduce serum triglyceride levels in mammals. Furthermore, example 5 provides support for the lowering of serum triglycerides in mammal, see example 5 (pages 25-28, particularly page 28, lines 4-10).

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

### Conclusion

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Rebecca L. Anderson whose telephone number is (571) 272-0696. Mrs. Anderson can normally be reached Monday through Friday 5:30AM to 2:00PM.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Mr. Joseph K. McKane, can be reached at (571) 272-0699.

The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/637,190 Page 5

Art Unit: 1626

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Rebecca Anderson Patent Examiner Art Unit 1626, Group 1620 Technology Center 1600

6/21/05

Joseph K. McKane Supervisory Patent Examiner Art Unit 1626, Group 1620 Technology Center 1600